No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:35:54.802Z. Latest historical point 2024-04-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Candel Therapeutics, Inc. (CADL) stock was $10.15 as of Oct 6, 2026, 10:35 AM EDT, down 0.78% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +83.5% · 3-year avg +128.2%/yr · 5-year avg -1.4%/yr
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients.
Biotechnology · Needham, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.35
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.36
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CADL | $743.69M | $10.15 | -0.78% | +83.46% | -1.42% | N/A | N/A |
| 2DSGN | $748.66M | $11.99 | -3.49% | +102.59% | -3.82% | N/A | vs CADL |
| 3CTKB | $738.70M | $5.72 | -6.08% | +53.09% | -23.16% | N/A | vs CADL |
| 4ATTO | $755.27M | $17.55 | -2.46% | N/A | N/A | N/A | vs CADL |
| 5MLAB | $766.58M | $136.99 | -3.68% | +94.75% | -13.52% | +2.29% | vs CADL |
| 6LXRX | $768.46M | $1.73 | -0.57% | +23.28% | -18.54% | -21.03% | vs CADL |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$21.75
+114.3% upside
Low
$15.00
Current
$10.15
High
$29.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.40 | $-0.35 | $-0.25 | 3 |
| Quarter ending Dec 2026 | $-0.37 | $-0.34 | $-0.31 | 2 |
| Quarter ending Mar 2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Quarter ending Jun 2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.46 | $-1.34 | $-1.08 | 4 |
| FY 2027 | $-1.83 | $-1.07 | $-0.16 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $2.48M | $2.48M | $2.48M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $23.25M | $92.50M | $168.06M | 7 |
| FY 2027 | $9.20M | $44.32M | $79.44M | 5 |
